Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceu
(NQ:
RARE
)
57.34
+0.59 (+1.04%)
Streaming Delayed Price
Updated: 11:12 AM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceu
< Previous
1
2
3
4
5
6
7
8
Next >
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
January 04, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
January 03, 2024
Data from at least 20 patients enrolled in dose expansion cohorts anticipated in the first half of 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Expert Ratings for Ultragenyx Pharmaceutical
December 08, 2023
Via
Benzinga
Analyst Ratings for Ultragenyx Pharmaceutical
November 03, 2023
Via
Benzinga
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
December 28, 2023
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81.
Via
Investor's Business Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
December 18, 2023
For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterol
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Earnings Outlook For Ultragenyx Pharmaceutical
November 01, 2023
Via
Benzinga
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
October 10, 2023
Via
Benzinga
Ultragenyx to Participate at Investor Conferences in November
November 20, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 17, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate in the Jefferies London Healthcare Conference
November 07, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
November 02, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
October 26, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 23, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 19, 2023
Gainers
Via
Benzinga
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Leading the Way in Thursday Trading Based on Percentage Gain
October 19, 2023
Via
Investor Brand Network
AT&T, Union Pacific, Las Vegas Sands And Other Big Stocks Moving Higher On Thursday
October 19, 2023
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 30 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
October 18, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
October 18, 2023
Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Stocks Fall As Bond Yields Hit Multi-Year Highs
October 18, 2023
The major indexes are firmly lower this afternoon, with both the Dow Jones Industrial Average and Nasdaq Composite down triple digits as bond yields rise.
Via
Talk Markets
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 17, 2023
Via
Benzinga
Ultragenyx Announces Proposed Public Offering of Common Stock
October 17, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Why Is Mereo BioPharma Stock Trading Higher Today?
October 16, 2023
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) released interim data from the Phase 2 portion of the Phase 2/3 Orbit
Via
Benzinga
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
October 16, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
October 14, 2023
From
Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
October 09, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.